Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation

1. A compound of formula (I):

wherein:

A is C 1 -C 3 alkylene;

X N;

R 3 is selected from the group consisting of:

W and Y are C;

Z is C:

R 1 is selected from the group consisting of C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, halogen, and OCF 3 ;

R 2 is H;

Het is selected from the group consisting of:

wherein:

R 6 is selected from the group consisting of OH and OCH 3 ;

R 7 is selected from the group consisting of H, CH 3 , NH 2 , and C 1 -C 3 alkylamino;

R 9 is selected from the group consisting of H and O, and the dashed bond represents the presence of a single or double bond;

and wherein the compounds can be in the form of a tautomer, a racemate, an enantiomer, a diastereomer, or a pharmaceutically acceptable salt.

2. The compound of claim 1 , wherein A is CH 2 .

3. The compound of claim 1 , wherein Het is:

4. The compound of claim 1 wherein Het is:

5. The compound of claim 1 selected from the group consisting of:

1-(5-Chloro-1-isobutyl-1H-indazol-7-ylmethyl)-1H-indazole-5-carboxylic acid methyl ester;

1-(5-Bromo-1-isobutyl-1H-indazol-7-ylmethyl)-1H-indazole-5-carboxylic acid methyl ester;

1-(5-Fluoro-1-isobutyl-1H-indazol-7-ylmethyl)-1H-indazole-5-carboxylic acid methyl ester;

1-(1-Isobutyl-5-trifluoromethyl-1H-indazol-7-ylmethyl)-1H-indazole-5-carboxylic acid methyl ester;

1-(1-Isobutyl-5-trifluoromethoxy-1H-indazol-7-ylmethyl)-1H-indazole-5-carboxylic acid methyl ester;

1-(5-Bromo-1-isopropyl-1H-indazol-7-ylmethyl)-1H-indazole-5-carboxylic acid methyl ester;

1-[5-Bromo-1-(2-ethyl-butyl)-1H-indazol-7-ylmethyl]-1H-indazole-5-carboxylic acid methyl ester;

1-[5-Chloro-1-(2-propyl)-1H-indazol-7-ylmethyl]-1H-indazole-5-carboxylic acid methyl ester;

1-(5-Chloro-1-isobutyl-1H-indazol-7-ylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid methyl ester;

1-(5-Chloro-1-isobutyl-1H-indazol-7-ylmethyl)-1H-benzoimidazole-5-carboxylic acid methyl ester;

3-(5-Chloro-1-isobutyl-1H-indazol-7-ylmethyl)-3H-imidazo[4,5-b]pyridine-6-carboxylic acid methyl ester;

1-(5-Chloro-1-isobutyl-1H-indazol-7-ylmethyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl ester;

1-(5-Bromo-1-isobutyl-1H-indazol-7-ylmethyl)-3-methyl-1H-indazole-5-carboxylic acid methyl ester;

1-(5-Bromo-1-isobutyl-1H-indazol-7-ylmethyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid methyl ester;

1-(1-Isobutyl-5-trifluoromethyl-1H-indazol-7-ylmethyl)-1H-benzoimidazole-5-carboxylic acid methyl ester;

1-(1-Isobutyl-5-trifluoromethoxy-1H-indazol-7-ylmethyl)-1H-benzoimidazole-5-carboxylic acid methyl ester;

Methyl 3-[(5-chloro-1-isobutyl-indazol-7-yl)methyl]imidazo[1,5-a]pyridine-7-carboxylate;

1-(5-Chloro-1-isobutyl-1H-indazol-7-ylmethyl)-2-oxo-2,3-dihydro-1H-indole-5-carboxylic acid methyl ester;

Methyl 3-amino-1-[(5-chloro-1-isobutyl-indazol-7-yl)methyl]indazole-5-carboxylate; and

Methyl 1-[(5-chloro-1-isobutyl-indazol-7-yl)methyl]-3-(methylamino)indazole-5-carboxylate;

or a pharmaceutically acceptable salt thereof.

6. A method of treating a patient suffering from a condition selected from the group consisting of inflammatory pain, neuropathic pain, visceral pain, fibrosis, the method comprising administering to said patient an effective amount of a compound of claim 1 .

7. A pharmaceutical composition comprising a compound of claim 1 and one or more pharmaceutically acceptable excipients.

8. A compound selected from the group consisting of:

Methyl 2-[[[2-(5-chloro-1-isobutyl-indazol-7-yl)acetyl]amino]methyl]pyridine-4-carboxylate; and

5-Bromo-1-(5-chloro-1-isobutyl-1H-indazol-7-ylmethyl)-1,3-dihydro-indol-2-one;

or a pharmaceutically acceptable salt thereof.

9. A method of treating a patient suffering from a condition selected from the group consisting of inflammatory pain, neuropathic pain, visceral pain, and fibrosis, the method comprising administering to said patient an effective amount of a compound of claim 8 .

10. A pharmaceutical composition comprising a compound of claim 8 and one or more pharmaceutically acceptable excipients.